弘訊科技(603015.SH):周筱龍減持期屆滿 累計減持4萬股
格隆匯 7 月 14日丨弘訊科技(603015.SH)公佈,此前披露,俞田龍、葉海萍、陰昆、於洋、鄭琴和周筱龍分別擬通過集中競價減持公司股份不超過2萬股,2萬股,2萬股,2萬股,1.5萬股和4萬股。葉海萍持有的股份其中1.8萬股來源於二級市場集中競價,另8萬股為2017年限制性股票激勵計劃授予的股份,擬減持的僅為2017年限制性股票激勵計劃授予的股份;其餘五位所持有股份均為2017年限制性股票激勵計劃授予的股份。
上述減持計劃於2020年7月13日期滿,減持計劃實施期間僅周筱龍通過集中競價交易方式累計減持公司股份4萬股,佔公司總股本的0.0098%。其餘五位均未實施減持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.